-
Je něco špatně v tomto záznamu ?
Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study
M. Santoni, ZW. Myint, T. Büttner, H. Takeshita, Y. Okada, ET. Lam, D. Gilbert, Z. Küronya, D. Tural, R. Pichler, E. Grande, SJ. Crabb, R. Kemp, F. Massari, S. Scagliarini, R. Iacovelli, N. Vau, U. Basso, M. Maruzzo, J. Molina-Cerrillo, L. Galli,...
Jazyk angličtina Země Německo
Typ dokumentu časopisecké články
NLK
PubMed Central
od 1982
Medline Complete (EBSCOhost)
od 2000-04-01
ROAD: Directory of Open Access Scholarly Resources
od 2002
- MeSH
- cisplatina terapeutické užití MeSH
- humanizované monoklonální protilátky farmakologie MeSH
- karcinom z přechodných buněk * patologie MeSH
- lidé MeSH
- nádory močového měchýře * farmakoterapie patologie MeSH
- protokoly protinádorové kombinované chemoterapie MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
BACKGROUND: The advent of immune-checkpoint inhibitors has challenged previous treatment paradigms for advanced urothelial carcinoma (UC) in the post-platinum setting as well as in the first-line setting for cisplatin-ineligible patients. In this study, we investigated the effectiveness of pembrolizumab as first-line treatment for cisplatin-ineligible UC. METHODS: Data from patients aged ≥ 18 years with cisplatin-ineligible UC and receiving first-line pembrolizumab from January 1st 2017 to September 1st 2022 were collected. Cisplatin ineligibility was defined according to the Galsky criteria. Thirty-three Institutions from 18 countries were involved in the ARON-2 study. RESULTS: Our analysis included 162 patients. The median follow-up time was 18.9 months (95%CI 15.3-76.9). In the overall study population, the median OS was 15.8 months (95%CI 11.3-32.4). The median OS was significantly longer in males versus females while no statistically significant differences were observed between patients aged < 65y versus ≥ 65y and between smokers and non-smokers. According to Recist 1.1 criteria, 26 patients (16%) experienced CR, 32 (20%) PR, 39 (24%) SD and 55 (34%) PD. CONCLUSIONS: Our data confirm the role of pembrolizumab as first-line therapy for cisplatin-unfit patients. Further studies investigating the biological and immunological characteristics of UC patients are warranted in order to optimize the outcome of patients receiving immunotherapy in this setting.
Department of Biomedical Sciences Humanitas University Pieve Emanuele Milan Italy
Department of Medical Oncology Centre Hospitalier de Jolimont Haine Saint Paul Belgium
Department of Medical Oncology Hospital Ramón y Cajal Madrid Spain
Department of Medical Oncology MD Anderson Cancer Center Madrid Madrid Spain
Department of Oncology IRCCS Humanitas Research Hospital Rozzano Milan Italy
Department of Oncology San Camillo Forlanini Hospital Rome Italy
Department of Urology Medical University of Innsbruck Anichstrasse 35 6020 Innsbruck Austria
Department of Urology Saitama Medical Center Saitama Medical University Saitama Japan
Department of Urology University Hospital Bonn 53127 Bonn Germany
Dipartimento di Oncologia Medica Fondazione IRCCS Istituto Nazionale dei Tumori Milan Italy
Division of Medical Oncology National Cancer Centre Singapore Singapore Singapore
Interdisciplinary Department of Medicine University of Bari Aldo Moro Bari Italy
Klinik für Urologie Ratzeburger Allee 160 23538 Lübeck Germany
Latin American Cooperative Oncology Group LACOG Porto Alegre Brazil
Markey Cancer Center University of Kentucky Lexington KY 40536 0293 USA
Medical Oncology IRCCS Azienda Ospedaliero Universitaria Di Bologna Via Albertoni 15 Bologna Italy
Medical Oncology Tawam Hospital Al Ain United Arab Emirates
Medical Oncology Unit Santa Chiara Hospital Trento Italy
Niguarda Cancer Center Grande Ospedale Metropolitano Niguarda Milan Italy
Oncologia Medica Fondazione Policlinico Universitario Agostino Gemelli IRCCS Rome Italy
Oncology and Hematology Department Hospital Santa Lucia SHLS 716 Cj C Brasília DF 70390 700 Brazil
Oncology Institute of Vojvodina Faculty of Medicine University Novi Sad Novi Sad Serbia
Oncology Unit 2 University Hospital of Pisa 56126 Pisa Italy
Oncology Unit Macerata Hospital Via Santa Lucia 2 62100 Macerata Italy
Southampton Experimental Cancer Medicine Centre University of Southampton Southampton UK
University of Colorado Cancer Center Anschutz Medical Campus Aurora CO USA
UOC di Oncologia Azienda Ospedaliera di Rilievo Nazionale Cardarelli di Napoli Naples Italy
Urologic Oncology Champalimaud Clinical Center 1400 038 Lisbon Portugal
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23016428
- 003
- CZ-PrNML
- 005
- 20231026105848.0
- 007
- ta
- 008
- 231013s2023 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s00262-023-03469-5 $2 doi
- 035 __
- $a (PubMed)37248424
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Santoni, Matteo $u Oncology Unit, Macerata Hospital, Via Santa Lucia 2, 62100, Macerata, Italy. mattymo@alice.it
- 245 10
- $a Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study / $c M. Santoni, ZW. Myint, T. Büttner, H. Takeshita, Y. Okada, ET. Lam, D. Gilbert, Z. Küronya, D. Tural, R. Pichler, E. Grande, SJ. Crabb, R. Kemp, F. Massari, S. Scagliarini, R. Iacovelli, N. Vau, U. Basso, M. Maruzzo, J. Molina-Cerrillo, L. Galli, A. Bamias, U. De Giorgi, PA. Zucali, M. Rizzo, E. Seront, L. Popovic, O. Caffo, S. Buti, R. Kanesvaran, J. Kopecky, J. Kucharz, A. Zeppellini, O. Fiala, J. Landmesser, J. Ansari, P. Giannatempo, A. Rizzo, IO. Zabalza, FSM. Monteiro, N. Battelli, F. Calabrò, C. Porta
- 520 9_
- $a BACKGROUND: The advent of immune-checkpoint inhibitors has challenged previous treatment paradigms for advanced urothelial carcinoma (UC) in the post-platinum setting as well as in the first-line setting for cisplatin-ineligible patients. In this study, we investigated the effectiveness of pembrolizumab as first-line treatment for cisplatin-ineligible UC. METHODS: Data from patients aged ≥ 18 years with cisplatin-ineligible UC and receiving first-line pembrolizumab from January 1st 2017 to September 1st 2022 were collected. Cisplatin ineligibility was defined according to the Galsky criteria. Thirty-three Institutions from 18 countries were involved in the ARON-2 study. RESULTS: Our analysis included 162 patients. The median follow-up time was 18.9 months (95%CI 15.3-76.9). In the overall study population, the median OS was 15.8 months (95%CI 11.3-32.4). The median OS was significantly longer in males versus females while no statistically significant differences were observed between patients aged < 65y versus ≥ 65y and between smokers and non-smokers. According to Recist 1.1 criteria, 26 patients (16%) experienced CR, 32 (20%) PR, 39 (24%) SD and 55 (34%) PD. CONCLUSIONS: Our data confirm the role of pembrolizumab as first-line therapy for cisplatin-unfit patients. Further studies investigating the biological and immunological characteristics of UC patients are warranted in order to optimize the outcome of patients receiving immunotherapy in this setting.
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a karcinom z přechodných buněk $x patologie $7 D002295
- 650 _2
- $a cisplatina $x terapeutické užití $7 D002945
- 650 12
- $a nádory močového měchýře $x farmakoterapie $x patologie $7 D001749
- 650 _2
- $a humanizované monoklonální protilátky $x farmakologie $7 D061067
- 650 _2
- $a protokoly protinádorové kombinované chemoterapie $7 D000971
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Myint, Zin W $u Markey Cancer Center, University of Kentucky, Lexington, KY, 40536-0293, USA
- 700 1_
- $a Büttner, Thomas $u Department of Urology, University Hospital Bonn (UKB), 53127, Bonn, Germany
- 700 1_
- $a Takeshita, Hideki $u Department of Urology, Saitama Medical Center, Saitama Medical University, Saitama, Japan
- 700 1_
- $a Okada, Yohei $u Department of Urology, Saitama Medical Center, Saitama Medical University, Saitama, Japan
- 700 1_
- $a Lam, Elaine T $u University of Colorado Cancer Center, Anschutz Medical Campus, Aurora, CO, USA
- 700 1_
- $a Gilbert, Danielle $u University of Colorado Cancer Center, Anschutz Medical Campus, Aurora, CO, USA
- 700 1_
- $a Küronya, Zsófia $u Department of Genitourinary Medical Oncology and Clinical Pharmacology, National Institute of Oncology, Budapest, Hungary
- 700 1_
- $a Tural, Deniz $u Department of Medical Oncology, Bakirköy Dr. Sadi Konuk Training and Research Hospital, Zuhuratbaba District, Tevfik Saglam St. No: 11, Bakirkoy, Istanbul, Turkey
- 700 1_
- $a Pichler, Renate $u Department of Urology, Medical University of Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria
- 700 1_
- $a Grande, Enrique $u Department of Medical Oncology, MD Anderson Cancer Center Madrid, Madrid, Spain
- 700 1_
- $a Crabb, Simon J $u Southampton Experimental Cancer Medicine Centre, University of Southampton, Southampton, UK
- 700 1_
- $a Kemp, Robert $u Southampton Experimental Cancer Medicine Centre, University of Southampton, Southampton, UK
- 700 1_
- $a Massari, Francesco $u Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Via Albertoni - 15, Bologna, Italy
- 700 1_
- $a Scagliarini, Sarah $u UOC di Oncologia, Azienda Ospedaliera di Rilievo Nazionale Cardarelli di Napoli, Naples, Italy
- 700 1_
- $a Iacovelli, Roberto $u Oncologia Medica, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
- 700 1_
- $a Vau, Nuno $u Urologic Oncology, Champalimaud Clinical Center, 1400-038, Lisbon, Portugal
- 700 1_
- $a Basso, Umberto $u Medical Oncology 1 Unit, Department of Oncology, Istituto Oncologico Veneto IOV IRCCS, 35128, Padua, Italy
- 700 1_
- $a Maruzzo, Marco $u Medical Oncology 1 Unit, Department of Oncology, Istituto Oncologico Veneto IOV IRCCS, 35128, Padua, Italy
- 700 1_
- $a Molina-Cerrillo, Javier $u Department of Medical Oncology, Hospital Ramón y Cajal, Madrid, Spain
- 700 1_
- $a Galli, Luca $u Oncology Unit 2, University Hospital of Pisa, 56126, Pisa, Italy
- 700 1_
- $a Bamias, Aristotelis $u 2nd Propaedeutic Department of Internal Medicine, School of Medicine, ATTIKON University Hospital, National and Kapodistrian University of Athens, Athens, Greece
- 700 1_
- $a De Giorgi, Ugo $u Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
- 700 1_
- $a Zucali, Paolo Andrea $u Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy $u Department of Oncology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy
- 700 1_
- $a Rizzo, Mimma $u Division of Medical Oncology, A.O.U. Consorziale Policlinico di Bari, Piazza G. Cesare 11, 70124, Bari, Italy
- 700 1_
- $a Seront, Emmanuel $u Department of Medical Oncology, Centre Hospitalier de Jolimont, Haine Saint Paul, Belgium
- 700 1_
- $a Popovic, Lazar $u Oncology Institute of Vojvodina, Faculty of Medicine, University Novi Sad, Novi Sad, Serbia
- 700 1_
- $a Caffo, Orazio $u Medical Oncology Unit, Santa Chiara Hospital, Trento, Italy
- 700 1_
- $a Buti, Sebastiano $u Medical Oncology Unit, Department of Medicine and Surgery, University Hospital of Parma, University of Parma, Parma, Italy
- 700 1_
- $a Kanesvaran, Ravindran $u Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore
- 700 1_
- $a Kopecky, Jindrich $u Department of Clinical Oncology and Radiotherapy, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
- 700 1_
- $a Kucharz, Jakub $u Department of Uro-Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
- 700 1_
- $a Zeppellini, Annalisa $u Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy
- 700 1_
- $a Fiala, Ondřej $u Department of Oncology and Radiotherapeutics, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic
- 700 1_
- $a Landmesser, Johannes $u Klinik für Urologie, Ratzeburger Allee 160, 23538, Lübeck, Germany
- 700 1_
- $a Ansari, Jawaher $u Medical Oncology, Tawam Hospital, Al Ain, United Arab Emirates
- 700 1_
- $a Giannatempo, Patrizia $u Dipartimento di Oncologia Medica, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
- 700 1_
- $a Rizzo, Alessandro $u Struttura Semplice Dipartimentale di Oncologia Medica per la Presa in Carico Globale del Paziente Oncologico "Don Tonino Bello", I.R.C.C.S. Istituto Tumori "Giovanni Paolo II", Bari, Italy
- 700 1_
- $a Zabalza, Ignacio Ortego $u Department of Medical Oncology, MD Anderson Cancer Center Madrid, Madrid, Spain
- 700 1_
- $a Monteiro, Fernando Sabino M $u Latin American Cooperative Oncology Group - LACOG, Porto Alegre, Brazil $u Oncology and Hematology Department, Hospital Santa Lucia, SHLS 716 Cj. C, Brasília, DF, 70390-700, Brazil
- 700 1_
- $a Battelli, Nicola $u Oncology Unit, Macerata Hospital, Via Santa Lucia 2, 62100, Macerata, Italy
- 700 1_
- $a Calabrò, Fabio $u Department of Oncology, San Camillo Forlanini Hospital, Rome, Italy
- 700 1_
- $a Porta, Camillo $u Division of Medical Oncology, A.O.U. Consorziale Policlinico di Bari, Piazza G. Cesare 11, 70124, Bari, Italy $u Interdisciplinary Department of Medicine, University of Bari "Aldo Moro", Bari, Italy
- 773 0_
- $w MED00001041 $t Cancer immunology, immunotherapy : CII $x 1432-0851 $g Roč. 72, č. 9 (2023), s. 2961-2970
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37248424 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20231013 $b ABA008
- 991 __
- $a 20231026105841 $b ABA008
- 999 __
- $a ok $b bmc $g 2000128 $s 1202790
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 72 $c 9 $d 2961-2970 $e 20230529 $i 1432-0851 $m Cancer immunology and immunotherapy $n Cancer Immunol Immunother $x MED00001041
- LZP __
- $a Pubmed-20231013
